Product
Supplier
Encyclopedia
Inquiry
Retatrutide RT30mg buy - large image1
Retatrutide RT30mg buy - image1
Retatrutide RT30mg buy - image2
Retatrutide RT30mg buy - image3
Retatrutide RT30mg buy - image4
Retatrutide RT30mg buy - image5

Retatrutide RT30mg

7208 Inquiries

Unit Price:

$189-210/MT EXW

Get Latest Price
CAS No.:

2381089-83-2

Grade:

Pharmaceutical Grade

Content:

99.5%

Packaging:

Carton

Price valid (until):

2027-07-31

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,100% TT in advance
Average Lead Time:
15 days
Qualification:
Main Products:

Peptide

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Retatrutide CAS NO.:2381089-83-2

    Purity:99.5%

    Product standard:5mg/10mg/15mg/20mg/30mg/40mg//60mg

    Storage:2-8℃(protect from light)

    Please check the product after you receive it. If there is no problem, please store the product in frost and keep the sample bottle sealed. The product can be stored for up to 24 months (2-8 degrees Celsius).



    Shop Retatrutide RT10mg-Detailed Image 1 Shop Retatrutide RT10mg-Detailed Image 2

    Shop Tirzepatide20 mg-Detailed Image 2

    Shop Tirzepatide20 mg-Detailed Image 3

    Shop Tirzepatide20 mg-Detailed Image 4


    Main Products:
    Our core business covers a variety of products, including weight loss peptides, pharmaceutical-grade peptides, cosmetic-grade peptides, and custom peptides. Among the weight loss peptide products, Semaglutide, Tirzepatide, Retatrutide, etc. stand out particularly.
    Clinical Efficacy:
    Clinical trials have confirmed that Semaglutide has significant efficacy. In a recent study, patients treated with Semaglutide experienced a notable weight loss. The research shows that Semaglutide activates the GLP-1 receptor to inhibit the appetite center in the hypothalamus, reducing hunger, thereby achieving the weight loss effect.

    Shop Tirzepatide20 mg-Detailed Image 5

    Shop Retatrutide 5mg-Detailed Image 7

    Shop Tirzepatide20 mg-Detailed Image 6


    Why choose us

    Our company has its own factory and is capable of large-scale production. We can meet your long-term and stable supply demands.
    We adhere to the principle of honest cooperation and service first. We have absolute product quality assurance, stable and efficient express delivery services, and provide comprehensive professional services. We warmly welcome your product inquiries and look forward to a stable cooperation with you.

    Shop Tirzepatide20 mg-Detailed Image 7

    Shop Tirzepatide20 mg-Detailed Image 8


    Company profile

    DeJia Peptide is a professional factory for beauty peptides and a reliable manufacturer of cosmetic peptides. It focuses on the research, production and global supply of high-purity beauty peptides.The company possesses advanced production technologies and a professional technical team. It attaches great importance to the consistency of product quality and sustainable production, and can meet the customized demands of different markets. The production adopts GMP-compliant production lines, with strict quality control to ensure the stability, safety and effectiveness of the products.

    The company is one of the most reliable suppliers of cosmetic peptides in the industry, with high purity, batch consistency and green sustainable production. It is suitable for enterprises that require a stable supply chain.

    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Categories:

    Polypeptide

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptide

    Location:

    Room Z567,17th Floor,BuildingA,No.298 Yanjiang Middle Road,Yuexiu District,Guangzhou

    Payment Terms:

    TT against copy of documents,100% TT in advance

    Average lead Time:

    15 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    5-10

    Year of Establishment:

    2026

  • Inquiry History
    7208 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Retatrutide 2381089-83-2

    3 MT Mar 28, 2026
    United Kingdom

    Retatrutide - 2381089-83-2

    1 G Feb 10, 2026
    United States

    Retatrutide CAS 2381089-83-2 10mg vial

    20 MT Mar 7, 2026
    United States

    Factory Retatrutide API 99% Purity CAS 2381089-83-2

    5 KG Nov 10, 2025
    United Kingdom

    Peptide powder Retatrutide 99% pure for Body building cas 2381089-83-2 Weight Loss Peptide with COA

    1 MT Mar 22, 2026
    United States

    2381089-83-2

    100 G Jul 14, 2026
    United States

    2381089-83-2

    100 G Feb 24, 2026
    United States

    2381089-83-2

    100 MT Dec 9, 2023
    United States

    Retatrutide 2381089-83-2

    200 MG May 16, 2026
    United Kingdom

    2381089-83-2 retatrutide

    300 MG Feb 13, 2026
    United States

    Retatrutide 2381089-83-2 wholesale

    500 MT Nov 3, 2023
    United States

    Retatrutide CAS 2381089-83-2 99%

    10 PCS Feb 21, 2026
    Poland

    CAS 2381089-83-2 (Custom Peptide)

    40 MT Apr 10, 2026
    Austria

    Peptide Retatruide CAS 2381089-83-2

    100 MT Apr 4, 2026
    Austria

    Retatrutide CAS 2381089-83-2 10mg vial

    20 PCS Feb 10, 2026
    United States

    GLP-1 / GIP Retatrutide cas 2381089-83-2

    1 MT Oct 16, 2024
    United States

    Retatrutide 99% High Quality CAS 2381089-83-2

    1 G Jan 23, 2026
    United States

    Injection Peptide Tirzepatide/Retatrutide/ Semaglutide Peptides CAS 2381089-83-2

    10  Oct 21, 2023
    Palestine

    Factory 99% Purity Retatrutide Peptide CAS 2381089-83-2 Door-To-Door Service

    10 MG Mar 16, 2026
    United States

    Factory 99% Purity Retatrutide Peptide CAS 2381089-83-2 Door-To-Door Service

    20 MG Feb 4, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.